Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Forest Laboratories

    - PMLiVE

    Minds + Assembly Launches Assembled Intelligence and Adds Stratevi to Expand Market Access and HEOR Solutions

    New York, NY — 10.23.2025 — Minds + Assembly, a leading healthcare marketing firm, today announced the launch of Assembled Intelligence, an integrated communications and commercialization platform designed to unite...

    BOLDSCIENCE

    - PMLiVE

    NICE backs Allergan’s IBS therapy Truberzi

    The £3 per day therapy was recommended in final guidance from the cost-effectiveness watchdog

    - PMLiVE

    Stada opens books to let formal bidding commence

    Cinven, Advent International and Bain Capital now have opportunity to revise their bids

    - PMLiVE

    Advent tops Cinven offer for Stada as third suitor looms

    Values the OTC and generics specialist at €3.6bn, with offer open until 27 February

    - PMLiVE

    Allergan adds Zeltiq to M&A roster in $2.48n deal

    Expands aesthetic pharma business with “best-in-class” body contouring system

    - PMLiVE

    Seattle Genetics signs $2bn deal for Immunomedics’ cancer drug

    Buys rights to breast cancer drug candidate that could be be in line for FDA approval by year end

    - PMLiVE

    Stada confirms Cinven as one of two takeover bidders

    Private equity group offers €3.6bn for the generics and over-the-counter medicines manufacturer

    - PMLiVE

    Cello Health expands with Defined Health acquisition

    Builds US presence with biotech-focused strategy specialist

    Celgene building

    Celgene pays $300m upfront for immunology start-up Delinia

    Broadens its pipeline with autoimmune disease candidate due to start trials in 2018

    Actelion HQ Switzerland

    J&J agrees $30bn deal to acquire Actelion

    Swiss biotech to retain control of early-stage pipeline as J&J takes minority stake in R&D spin-out

    - PMLiVE

    Merck pays Vertex $230m upfront for cancer programmes

    Licences four DNA damage and repair programmes with first-in-class or best-in-class potential

    - PMLiVE

    Ipsen buys cancer business from stripped down Merrimack

    Deal includes pancreatic cancer therapy Onivyde which it hopes will gain first-line approval

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links